StockNews.AI
CERS
StockNews.AI
167 days

Cerus Corporation Announces Receipt of CE Mark for Next-Generation INTERCEPT Illumination Device (INT200)

1. CERS received CE mark approval for its INT200 device in the EU. 2. This approval enables expanded marketing opportunities for CERS's blood system products.

2m saved
Insight
Article

FAQ

Why Bullish?

CE mark approval typically enhances market potential and investor interest. Similar approvals in the past positively affected stocks in the medical device sector.

How important is it?

CE mark approval is significant for expansion, though immediate sales are contingent on further regulatory steps.

Why Short Term?

Immediate marketability in the EU may lead to quick revenue impacts. However, additional country-specific approvals may delay sales.

Related Companies

ABTBDXTMO
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today the CE mark approval of its next-generation LED-based illumination device, or the INT200, for the INTERCEPT Blood System for platelets and plasma under the European Union (EU) Medical Device Regulation (MDR). This approval allows Cerus to market the INT200 throughout the EU and in other regions that recognize the CE mark. Some countries may require additional in-country regulatory approval prior to commercializat.

Related News